Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Unite Group (UTG) by Sumayya Mansoor in The Motley Fool
- Overweight AstraZeneca (AZN) by Barclays
- Buy Tesco (TSCO) by Kepler Cheuvreux
- Buy Anpario (ANP) by Hot Stock Rockets in ShareProphets
- Sell Directa Plus (DCTA) by Steve Moore in ShareProphets
- Buy React Group (REAT) by Hot Stock Rockets in ShareProphets
- Avoid Iomart Group (IOM) by Steve Moore in ShareProphets
- Sell Lifesafe Holdings (LIFS) by Steve Moore in ShareProphets
- Sell Petrofac Ltd. (PFC) by Tom Winnifrith in ShareProphets
- Neutral Ashmore Group (ASHM) by UBS
- Hold CRH (CDI) (CRH) by Stifel
- Hold Severn Trent (SVT) by Deutsche Bank
- Hold Pennon Group (PNN) by Deutsche Bank
- Hold United Utilities Group (UU.) by Deutsche Bank
- Neutral Mondi (MNDI) by Exane
- Outperform SSP Group (SSPG) by RBC Capital
- Outperform Associated British Foods (ABF) by RBC Capital
- Outperform IMI (IMI) by RBC Capital
- Buy Intertek Group (ITRK) by Berenberg
- Sector Perform Hilton Food Group (HFG) by RBC Capital
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 59 open tips for Shield Therapeutics (STX)
| Latest Bid : 1.50p | Latest Ask : 1.55p |
| High Today : 1.55p | Low Today : 1.50p |
| This Years High : 12.50p | This Years Low : 1.50p |
| Volume : 1,654,858 | MKT Cap : £12.12M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2022-02-18 10:45:00 18/02/2022 | 93.92% |
| Buy | Royston Wild | Premium Only | 2021-08-24 07:40:00 24/08/2021 | -96.70% |
| Buy | Peel Hunt | Premium Only | 2021-06-24 18:00:00 24/06/2021 | -97.28% |
| Buy | Peel Hunt | Premium Only | 2020-03-17 15:35:00 17/03/2020 | -93.57% |
| Buy | Peel Hunt | Premium Only | 2020-03-05 10:10:00 05/03/2020 | -94.41% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.50p | Latest Ask : 1.55p |
| High Today : 1.55p | Low Today : 1.50p |
| This Years High : 12.50p | This Years Low : 1.50p |
| Volume : 1,654,858 | MKT Cap : £12.12M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2022-02-18 10:45:00 18/02/2022 | 93.92% |
| Buy | Royston Wild | Premium Only | 2021-08-24 07:40:00 24/08/2021 | -96.70% |
| Buy | Peel Hunt | Premium Only | 2021-06-24 18:00:00 24/06/2021 | -97.28% |
| Buy | Peel Hunt | Premium Only | 2020-03-17 15:35:00 17/03/2020 | -93.57% |
| Buy | Peel Hunt | Premium Only | 2020-03-05 10:10:00 05/03/2020 | -94.41% |